New drug combo offers hope for rare penile cancer
NCT ID NCT05526989
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs, dostarlimab and niraparib, can shrink tumors or slow the growth of advanced penile cancer in patients whose cancer has worsened after chemotherapy. About 25 adults with stage III or IV penile cancer will receive the combination treatment. The goal is to see if the drugs can control the disease and improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PENILE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.